ASHP

Targeted therapy in the management of non–small-cell lung cancer is discussed. Read More ›

Real-World Impact of Prophylactic Pegfilgrastim in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Receiving Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With or Without Rituximab Chemotherapy in Korea

Conference Correspondent, ASHP

Conference Correspondent

Prophylactic pegfilgrastim was associated with fewer neutropenic events in patients receiving a CHOP-based regimen in DLBCL. Read More ›

Comparison of Efficacy and Cost-Effectiveness of Filgrastim, tbo-Filgrastim, and Filgrastim-sndz in Patients with Cancer Receiving Myelosuppressive Chemotherapy and Patients with Severe Chronic Neutropenia

Conference Correspondent, ASHP

Conference Correspondent

An analysis of the efficacy and cost-effectiveness of 3 colony-stimulating factors— filgrastim, tbo-filgrastim, and filgrastim-sndz—is presented. Read More ›

Personalizing Patient Management and Oral Adherence for the Oncology Patient

Conference Correspondent, ASHP

Conference Correspondent

The role of the oncology pharmacist in promoting oral adherence for the oncology patient is discussed. Read More ›

Latest Developments in Short-Acting Granulocyte Colony-Stimulating Factor (G-CSF) Treatment Options: The First FDA-Approved Biosimilar, Zarxio® (filgrastim-sndz)

Conference Correspondent, ASHP

Conference Correspondent

Biosimilarity between Zarxio and Neupogen is proven through PIONEER study results. Read More ›